ABSTRACT
Cholestatic liver diseases (CLD) are a series of hepatobiliary diseases characterized by dysfunction of bile formation, secretion and excretion and are induced by immune, genetic and environmental factors. The development and pathogenesis of CLD is still unclear, and it has a risk of progression to liver fibrosis and cirrhosis. Traditional medicines such as ursodeoxycholic acid (UDCA), glucocorticoids and immunosuppressants have certain limitations. More and more studies provide new insights into the mechanism of cholestasis to explore the therapeutic targets, and various drugs such as all-trans retinoic acid, microecologics and norursodeoxycholic acid emerge as new therapeutic drugs. This article reviewed the advances in treatment of CLD.
ABSTRACT
OBJECTIVE:To study the improvement of Zea mays extract on cholestatic liver diseases.METHODS: Acute cholestatic liver injury model of rat was induced by bile duct ligation and cholestatic liver model of rats was established by ANIT.Model rats were given 6.2 g?kg-1 and 3.1 g?kg-1 dose of Z.mays extract for 5 days.The content of TBIL,DBIL,ALT,AST and TBA in serum and the secretion of bile were determined.RESULTS: The corn stigma extract decreased the content of DBIL,ALT and TBA in serum of ANIT-inducing cholestatic liver model,and increased the flow and speed of bile (P
ABSTRACT
Children with chronic cholestasis usually have pruritus, jaundice, failure to thrive and later, develop diliary cirrhosis. Ursodeoxycholic acid (UDCA) is a tertiary bile acid which has a positive effect on decreasing cholestasis. The aim of this study is to determine the efficacy of the drug on hepatic functions and symptoms in such patients. Nine children (six boys, three girls) diagnosed with biliary atresia (six cases), idiopathic neonatal hepatitis (two cases) and cryptogenic cirrhosis (one cases), received UDCA in a dose of 15 mg/kg daily for one year. Clinical features, symptoms and liver function tests were evaluated initially and at 1369 and 12 months after starting therapy. Seven patients had a complete 12-month therapy, but two patients were treated for only six months. Decreased cholestatis parameters were found including bilirubin from 11.7+ 4.9 to 7.7+ 3.2 mg/dl, GGT from 637.1+ 146.6 to 328.3+ 59.4 U/L, and AP from 1112.6+ 89.1 787.3+ 103.1 U/L., but there were no statistically significant results. Pruritus was improved in two of four patient with pruritus patients while four patients showed improved appetite.